Microdose Article: Which Psychedelic Medicine Companies Have the Best Financials?

Yes, of course, it matters greatly who has the most effective medical psychedelic molecule in specific circumstances. However, a company may be in possession of the most healing psychedelic compound in the world, but unless they can prove it through the clinical trial process, their superior medicine will mean little.

And unfortunately, to take a medicine from pre-clinical studies through Phase 1, 2, and 3 trials costs money. A LOT of money. For example, the US Congressional Budget Office estimates that the total cost of successfully bringing a new medicine through Phase 1, 2 and 3 trials is about $375 million USD.

Again, this means one of the — if not THE — determining factors in which of the dozens of psychedelic companies will survive long enough to make an eventual profit off of their medicines (and more importantly heal millions of people) is how financially stable said company is.

So: Which Psychedelic Medicine Companies Have the Best Financials? In this article, I will run through the top publicly traded psychedelic medicine companies, and assess their basic financial positions. 

It’s important to understand that a strong financial position now does not guarantee that a company will ultimately be successful. That company could still fail in a myriad of different ways — for example, if its medicine is less effective than another company’s. But, a company with disastrous financials will likely not even get the chance to be successful — even if its medicine is superior.

To start, let’s first understand the basic metrics we will be looking at. These are:

Read full article at 

Which Psychedelic Medicine Companies Have the Best Financials?

Primary Sponsor

 


Karma Koala Podcast

Top Marijuana Blog